Provides eligible underinsured individuals with financial assistance to cover all or part of the individuals’ out-of-pocket cost for the supported medications.Offers co-pay assistance program for infantile spasms only.To learn more about these programs, contact Access Pathways® at the number above. Access Pathways® provides co-pay and patient assistance for eligible patients.Additional 7-day supply will be dispensed as needed if there are further delays due to insurance approval (up to 28 days per starter prescription).Starter Prescription / Bridge Prescription will provide a 7-day supply if there is any delay in getting a prescription filled (prior authorization, weekend, insurance change).Available for new and existing patients.For eligibility requirements, contact the Patient Assistance Resource numbers above. For eligible patients, PAR provides co-pay assistance and patient assistance programs.A second 5-day supply will be dispensed on an as-needed basis during insurance approval.“Quick Start” pack will provide a 5-day supply for those requiring prior authorization.Only for commercially insured patients one month to 2 years old with a confirmed diagnosis of infantile spasms.Co-Pay Assistance where alternate funding assistance is not available for commercially insured patients (those without Medicare Part D or Medicaid).Patient Assistant Program offers no-cost product for those who do not qualify for coverage, co-pay or alternate funding.A second 5-day supply will be available for patients experiencing longer delays for coverage.“Quick Start Shipments” provide a 5-day supply of product where a PA or appeal will take more than 24 hours to resolve.Help with benefits verification and prior authorizations (PAs) and appeals.For more information, contact the Lundbeck Patient Assistance Program at 1-83. Other patient assistance may also be available.Download this PDF for eligibility information. Co-pay assistance may be available for commercially insured patients.No bridge supply offered for ongoing prescription.Only new commercially insured patients one month to 2 years old with a confirmed diagnosis of infantile spasms and registered in the REMS system are eligible for a one-time 30-day supply while receiving insurance approval.Upsher-Smith Vigadrone ® for Oral Solutions, Access Pathways ® Program SupportĨ6 (Monday-Friday 8 a.m. ET)Īmneal Pharmaceuticals Generic Vigabatrin for Oral SolutionĨ7 (Monday to Friday, 8 a.m. Lundbeck Sabril®Ĩ8 (Monday to Friday, 8 a.m. African Sun Limited (ASUN.Important Updates About Vigabatrin and Patient Assistance Patient Assistance Programs for Sabril® and Currently Available Generic Vigabatrinĭue to recent challenges reported by patients and healthcare providers, the following table was developed to help you and your healthcare provider understand currently available patient assistance programs and their requirements for Lundbeck Sabril ® and generic vigabatrin products offered by PAR Pharmaceutical, Amneal and Upsher-Smith as well as a private foundation offering help with co-pays.Shareholders who have not yet submitted their banking details or whose banking details have changed from the date of the last submission are requested to submit the same to our transfer secretaries who are Corpserve Registrars (Private) Limited situated at:Ĭnr 1st and Kwame Nkrumah Avenue, Harare, Zimbabweīally House, Mount Pleasant Business Park,Ĭorner Norfolk Road/870 Endeavour Crescent, Harare, Zimbabwe. Non-resident shareholders’ tax and resident shareholders’ tax will be deducted from the gross dividends where applicable. The shares of the Company will be traded cum-dividend (“with dividend”) on the Zimbabwe Stock Exchange (“the ZSE”) up to the market day of Tuesday, and ex-dividend from Wednesday. The payment of the dividend will take place on or before Tuesday. The Company generated an inflation adjusted profit before tax of ZWL9,771,234,879 and a profit after tax of ZWL9,737,406,796 for the year ended 31 December 2021. The dividend is payable out of the 2021 financial year profits to all shareholders of the Company registered as at the close of business on Friday. NOTICE IS HEREBY GIVEN THAT, the Board of Directors of African Sun Limited (“the Company”) has declared a final dividend of ZWL0.0815947 per share (ZWL116,151,461) plus an additional USD0.0003548 per share (USD505,064) payable in respect of all ordinary shares of the Company.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |